ArticleEndocrine, metabolic & immune disorders drug targets2025

Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis.

Jing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.